- Report
- February 2024
- 170 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- February 2024
- 174 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- February 2024
- 190 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- January 2024
- 182 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- January 2024
- 181 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- January 2024
- 182 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- November 2023
- 189 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- November 2023
- 182 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- November 2023
- 190 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- November 2023
- 180 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- October 2023
- 178 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- October 2023
- 173 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- October 2023
- 188 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- February 2024
- 120 Pages
Global
From €4564EUR$4,750USD£3,924GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1201EUR$1,250USD£1,033GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1201EUR$1,250USD£1,033GBP
- Clinical Trials
- April 2024
- 70 Pages
Global
From €1441EUR$1,500USD£1,239GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1201EUR$1,250USD£1,033GBP
- Drug Pipelines
- January 2024
- 80 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €2402EUR$2,500USD£2,066GBP
Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more